Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Antimicrobial Resistance

    Naval Research Laboratory Seeks to Advance Field Diagnostics of Infectious Agents

    By Global Biodefense StaffSeptember 21, 2018
    Share
    Facebook LinkedIn Reddit Email

    The Naval Research Laboratory (NRL) is seeking partners to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military and specifically for field deployment.

    Proposals for both genomic and immuno-analysis technologies are sought under this Multiechelon Diagnostics (MEDx) Technology Development and Tiered Evaluation Broad Agency Announcement (BAA) topic. Devices must be a low-complexity diagnostic device usable by personnel following minimal training.   A total sample to answer timeframe of one hour or less is preferred.  The final technology package should be for use in field forward, often austere environments with limited resources.

    Important assumptions for these environments include that they have no surgical and limited patient holding capability, are manned by a Physician, Physician Assistant (PA), or Medic, with the mission of providing triage, and treatment to return military personnel to duty, or stabilizing them for evacuation to the next level care facility. The device must have communications ability or can be easily integrated with a communication capability.

    Genomic Analysis Platforms

    NRL seeks to advance devices capable of detecting specific nucleic acid targets and/or examining molecular sequences at clinically relevant concentrations in complex clinical sample matrices, to include whole blood, serum/plasma, urine, and nasal swabs.

    Analysis should be multiplexed (minimum of four; preferred more than 5, including internal positive controls. Sample controls and negative template controls are also encouraged to provide a syndromic approach to disease identification; including sub-typing for diseases as appropriate (e.g., dengue virus serotypes 1, 2, 3, and 4, phylogenetic differentiation of Ebola strains).

    High Performance Non-Nucleic Acid Analysis Platforms

    Devices capable of identification of affinity ligand binding antigen capture (e.g., immunoassay target platforms that promote identification of the causative agent of illness are sought.

    Analysis should be multiplexed (minimum of three, preferred more than 4) to provide a syndromic approach to disease identification; including sub-classification for diseases as appropriate.  Assays for immunological targets that indicate acute infections are preferred, particularly for deployment in endemic areas.

    It is not required that the device is handheld, but the physical parameters of weight and footprint will be evaluated.  The Devices and Assays should be designed to diagnosis diseases whose origin is an infectious agent, pathogen, or toxin (organized as panels by syndromic presentation or pathogen class), and/or biomarkers of exposure to said agents.  Analytes of interest include both pathogen and host-related exposure class-differential diagnostic markers.

    The ability to differentiate between pathogens that cause non-specific febrile systemic disease that needs to be differentially ruled in (and preferably ruled out) such as Malaria (specifically P. falciparum), Arboviral diseases (e.g. dengue, chikungunya, etc.), Typhoid, Arenaviral diseases, Rickettsial diseases, Viral hemorrhagic fevers (specifically Lassa fever and Ebola), Plague, Tularemia (Francisella tularensis), and melioidosis (Burkholderia pseudomallei) is desirable.

    The government is also highly interested in capabilities for the rapid analysis of Antimicrobial/Multi-drug resistance (AMR/MDR) sensitivity.

    NRL will work cooperatively with the Offeror to test and verify performance of the devices and to assist in the integration of the diagnostic devices with communication and device hardening for Echelon 1 application.

    It is anticipated that the MEDx program will provide up to two years of funding for research and development through competitive prototyping.

    Additional details are available via Funding Opportunity Number: N00173-18-S-BA01. This BAA is estimated to remain open until May 10, 2019 (approximately one year from the date of publication), or until replaced by a successor BAA.

    Arenavirus Burkholderia Chikungunya Dengue Ebola F. tularensis Lassa Fever Malaria Melioidosis POC Diagnostics Ruggedized Y. pestis
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleFundamental Research to Counter Biological, Chemical, and Nuclear Weapons
    Next Article Focus on Melioidosis: Highlighted News and Research

    Related Stories

    Black Death Impact on Microbiome May Have Contributed to Modern-Day Chronic Diseases

    November 29, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    APHIS Announces Funding for Tribes to Support Animal Disease Preparedness and Response

    October 24, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.